Boehringer Ingelheim And IBM Collaborate To Advance Generative AI And Foundation Models For Therapeutic Antibody Development
IBM News, Tuesday, November 28,2023
Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.
'We are very excited to collaborate with the research team at IBM, who share our vision of making in silico biologic drug discovery a reality,' said Andrew Nixon, Global Head of Biotherapeutics Discovery at Boehringer Ingelheim. 'I am confident that by joining forces with IBM scientists we will develop an unprecedented platform for accelerated antibody discovery which will enable Boehringer to develop and deliver new treatments for patients with high unmet need.'